Skip to main content

Table 2 Clinicopathological data of breast cancer patients of validation cohort #2

From: Overexpression of circulating MiR-30b-5p identifies advanced breast cancer

Clinicopathological features Localized BrC Advanced BrC
Patients (n) 20 25
Age median (range) 61 (39–71) 53 (35–82)
Molecular subtypea (%)
 Luminal A-Like 7 (35.0) 2 (8.0)
 Luminal B-Like 13 (65.0) 16 (64.0)
 HER2-enriched 5 (20.0)
 Basal-like 2 (8.0)
Histological type (%)
 Invasive carcinoma of NST 17 (85.0) 18 (72.0)
 Invasive lobular carcinoma 2 (10.0) 4 (16.0)
 Other special subtype carcinoma 2 (8.0)
 Mixed type carcinoma 1 (5.0) 1 (4.0)
Grade (%)
 G1 4 (20.0)
 G2 9 (45.0) 19 (76.0)
 G3 7 (35.0) 6 (24.0)
ER receptor status (%)
 Positive 20 (100.0) 18 (72.0)
 Negative 7 (28.0)
PR receptor status (%)
 Positive 20 (100.0) 14 (56.0)
 Negative 11 (44.0)
HER2 receptor status (%)
 Positive 4 (20.0) 11 (44.0)
 Negative 16 (80.0) 14 (56.0)
T Stage (%)
 T1 20 (100.0) 3 (12.0)
 T2 11 (44.0)
 T3 5 (20.0)
 T4 6 (24.0)
N Stage (%)
 N0 20 (100.0)
 N1 4 (16.0)
 N2
 N3 20 (80.0)
 Nx 1 (4.0)
Stage (%)
 IA 20 (100.0) n.a.
 IIIC n.a. 13 (52.0)
 IV n.a. 12 (48.0)
  1. BrC breast cancer, ER estrogen receptor, G grade, HER2 human epidermal growth factor receptor 2, n.a. not applicable, NST no special type, PR progesterone receptor
  2. aAssessed by immunohistochemistry